

Nobivac NXT HCPChFeLV (--) + (--) + (--) + (--) + (--) - Lyophilisate and solvent for suspension for injection

Authorised

- Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient
- Chlamydia felis, strain Baker, Live
- Feline panleucopenia virus, strain MW-1, Live
- Feline calicivirus, strain F9, Live
- Felid herpesvirus 1, strain G2620A, Live

Product identification

Medicine name:

Nobivac NXT HCPChFeLV (--) + (--) + (--) + (--) + (--) - Lyophilisate and solvent for suspension for injection

Active substance:

Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient

Chlamydia felis, strain Baker, Live

Feline panleucopenia virus, strain MW-1, Live

Feline calicivirus, strain F9, Live

Felid herpesvirus 1, strain G2620A, Live

Target species:

Cat

Route of administration:

Subcutaneous use

Product details

Active substance and strength:

Feline leukemia virus (strain A/Glasgow-1), gp85 gene encoded by Venezuelan equine encephalitis virus (strain TC-83), self-amplifying RNA, viral particle, replication deficient

Chlamydia felis, strain Baker, Live

Feline panleucopenia virus, strain MW-1, Live

Feline calicivirus, strain F9, Live

Felid herpesvirus 1, strain G2620A, Live

Pharmaceutical form:

Lyophilisate and solvent for suspension for injection

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI06AX

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging: Vial (glass), Package_size: Lyophilisate: 25 vials + solvent: 25 vials,

Content: Lyophilisate: 1 dose + solvent: 0.5 ml

Packaging: Vial (glass), Package_size: Lyophilisate: 5 vials + solvent: 5 vials,

Content: Lyophilisate: 1 dose + solvent: 0.5 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - new active substance (Article 8 of Regulation (EU) 2019/6)

Marketing authorisation holder:

Intervet International B.V.

Marketing authorisation date:

29/07/2026

Manufacturing sites for batch release:

Intervet International B.V.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

29/07/2026

To consult adverse reactions on veterinary medicinal products please go to
www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 25/08/2026

[Download](#)